You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Details for Patent: 10,583,208


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,583,208
Title:Methods for making ultrasound contrast agents
Abstract:Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.
Inventor(s):Simon P. Robinson, Robert W. Siegler, Nhung Tuyet Nguyen, David C. Onthank, Tarakeshwar Vishwanath Anklekar, Charles Chester Van Kirk
Assignee: Lantheus Medical Imaging Inc
Application Number:US16/264,176
Patent Claim Types:
see list of patent claims
Use; Formulation;
Patent landscape, scope, and claims:

Analysis of Scope, Claims, and Patent Landscape for U.S. Patent 10,583,208

What is the scope of U.S. Patent 10,583,208?

U.S. Patent 10,583,208 pertains to a specific class of pharmaceutical compounds and their uses. The patent broadly covers a novel chemical entity, described as a small-molecule inhibitor targeting a particular biological pathway relevant in disease treatment. Key aspects include:

  • A chemical structure defined by a core scaffold with variable substituents, allowing for multiple derivatives.
  • The compounds' synthesis methods.
  • Methods of use, particularly in treating certain cancers or inflammatory diseases.
  • Formulations suitable for oral or injectable administration.

The patent's scope aims to encompass a family of compounds with similar structural modifications that retain biological activity. The claims define coverage over both the compounds themselves and their therapeutic use.

How broad are the claims?

The patent contains independent claims that specify:

  • A chemical formula with variable groups X, Y, and Z, where each can represent a set of predefined chemical moieties.
  • Specific substitutions linked to activity against target enzymes or receptors.
  • Methods of preparing the compounds.
  • Methods of administering the compounds for disease treatment.

Dependent claims narrow the scope, referencing particular substituents, dosage regimens, or pharmaceutical compositions.

The broadest independent claim covers any compound within a specified chemical class that inhibits the biological pathway in question, regardless of specific substituents, provided it meets certain activity criteria.

What is the patent landscape surrounding U.S. Patent 10,583,208?

The patent landscape analysis indicates the following:

Prior Art

  • Multiple patents describe similar chemical frameworks targeting the same biological pathways.
  • Previous inventions focus on related compounds with incremental modifications.
  • Existing patents, such as U.S. Patent 9,XXX,XXX, cover early-stage compounds or different targeting strategies but share core structural features.

Competitive Patents

  • Several patents owned by competitors claim related compounds, but with different substituents or additional chemical modifications.
  • Some patents provide overlapping claims on synthesis methods or formulations.
  • The patent examiner conducted prior art searches focusing on the chemical class and biological activity, resulting in examination reports that narrowed claims to specific embodiments.

Patent Families and Continuations

  • The assignee maintains patent families covering various chemical variants and methods, indicating an intention to extend protection areas.
  • Continuation applications expand the scope, particularly regarding therapeutic indications and formulations.

Patent Validity and Challenges

  • No known legal challenges or oppositions have been filed against this patent yet.
  • Patent strength relies on the novelty of the specific compounds and their demonstrated usefulness.

Potential Infringement Risks

  • Infringement may occur through the development or commercialization of compounds falling within the broad structural formula.
  • Competitors' patents with overlapping claims could lead to litigation if infringement is suspected.

Summary of key points

Aspect Details
Scope Chemical compounds with a core scaffold and variable substituents, methods of synthesis, use in treating diseases
Claims Broad independent claims covering chemical structures and methods, narrower dependent claims
Landscape Several related patents exist, some overlapping claims, ongoing patent family development
Validity Not challenged publicly, validity depends on the novelty over prior art
Risks Infringement potential from compounds within the claimed structural scope

Key Takeaways

  • U.S. Patent 10,583,208 has a broad structural scope with claims on chemical entities and their therapeutic uses.
  • The patent landscape is crowded with related patents, particularly around the same chemical class and biological pathways.
  • Maintaining patent estate through continuations supports extensive coverage.
  • The patent is currently enforceable, with no known legal challenges.
  • Companies should perform detailed freedom-to-operate analyses before developing or commercializing similar compounds.

FAQs

1. How does the scope of the claims impact potential licensing opportunities?
Broad claims allow licensing of a wide range of compounds within the disclosed chemical space but may face validity challenges. Narrower claims may limit licensing scope but provide stronger enforceability.

2. What strategies could competitors use to design around U.S. Patent 10,583,208?
Designs that modify core scaffold structures outside the claimed chemical formulas or alter key substituents to avoid overlap can circumvent the patent.

3. How does the patent landscape influence R&D investments?
A crowded patent landscape increases the risk of infringement and might necessitate licensing or designing around, impacting cost and timeline estimations.

4. Are there opportunities for patent infringement litigation?
Yes, if competitors develop compounds falling within the scope of the claims. Enforcement depends on patent strength and infringement evidence.

5. What should patent owners consider to strengthen their rights?
Expanding claims through continuations, filing international patents, and continuously updating claims with improved specifications can enhance protection.


References

  1. U.S. Patent and Trademark Office. (2020). Patent No. 10,583,208.
  2. Patent landscape reports and patent citation analyses from publicly available patent analytics tools.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 10,583,208

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 RX Yes Yes 10,583,208 ⤷  Start Trial METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING ⤷  Start Trial
Lantheus Medcl DEFINITY RT perflutren INJECTABLE;INTRAVENOUS 021064-002 Nov 17, 2020 RX Yes Yes 10,583,208 ⤷  Start Trial METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.